GSK Eases Cervarix Out Of India, Eyes On Trajectory Of Synflorix

GSK discontinues Cervarix in India as part of portfolio rationalization efforts against the backdrop of the arrival of Serum’s 'affordable' quadrivalent HPV vaccine. The heat is also believed to be on the UK drugmaker’s pneumococcal vaccine Synflorix in the country.

Changing Marketing Dynamics For HPV Vaccines In India • Source: Shutterstock

GlaxoSmithKline Pharmaceuticals Ltd. has eased out its bivalent human papillomavirus (HPV) vaccine, Cervarix, from the Indian market amid signs of low demand and the imminent debut of Serum Institute of India Pvt. Ltd.’s cut-price indigenous rival product.

GSK’s response to the “writing on the wall” as one observer put it, is significant coming at a time when...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip